Warm autoimmune hemolytic anemia

Revision as of 17:26, 20 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Jump to navigation Jump to search

Template:DiseaseDisorder infobox

WikiDoc Resources for Warm autoimmune hemolytic anemia

Articles

Most recent articles on Warm autoimmune hemolytic anemia

Most cited articles on Warm autoimmune hemolytic anemia

Review articles on Warm autoimmune hemolytic anemia

Articles on Warm autoimmune hemolytic anemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Warm autoimmune hemolytic anemia

Images of Warm autoimmune hemolytic anemia

Photos of Warm autoimmune hemolytic anemia

Podcasts & MP3s on Warm autoimmune hemolytic anemia

Videos on Warm autoimmune hemolytic anemia

Evidence Based Medicine

Cochrane Collaboration on Warm autoimmune hemolytic anemia

Bandolier on Warm autoimmune hemolytic anemia

TRIP on Warm autoimmune hemolytic anemia

Clinical Trials

Ongoing Trials on Warm autoimmune hemolytic anemia at Clinical Trials.gov

Trial results on Warm autoimmune hemolytic anemia

Clinical Trials on Warm autoimmune hemolytic anemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Warm autoimmune hemolytic anemia

NICE Guidance on Warm autoimmune hemolytic anemia

NHS PRODIGY Guidance

FDA on Warm autoimmune hemolytic anemia

CDC on Warm autoimmune hemolytic anemia

Books

Books on Warm autoimmune hemolytic anemia

News

Warm autoimmune hemolytic anemia in the news

Be alerted to news on Warm autoimmune hemolytic anemia

News trends on Warm autoimmune hemolytic anemia

Commentary

Blogs on Warm autoimmune hemolytic anemia

Definitions

Definitions of Warm autoimmune hemolytic anemia

Patient Resources / Community

Patient resources on Warm autoimmune hemolytic anemia

Discussion groups on Warm autoimmune hemolytic anemia

Patient Handouts on Warm autoimmune hemolytic anemia

Directions to Hospitals Treating Warm autoimmune hemolytic anemia

Risk calculators and risk factors for Warm autoimmune hemolytic anemia

Healthcare Provider Resources

Symptoms of Warm autoimmune hemolytic anemia

Causes & Risk Factors for Warm autoimmune hemolytic anemia

Diagnostic studies for Warm autoimmune hemolytic anemia

Treatment of Warm autoimmune hemolytic anemia

Continuing Medical Education (CME)

CME Programs on Warm autoimmune hemolytic anemia

International

Warm autoimmune hemolytic anemia en Espanol

Warm autoimmune hemolytic anemia en Francais

Business

Warm autoimmune hemolytic anemia in the Marketplace

Patents on Warm autoimmune hemolytic anemia

Experimental / Informatics

List of terms related to Warm autoimmune hemolytic anemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Warm Antibody Autoimmune Hemolytic Anemia (AIHA) is the most common of the autoimmune hemolytic diseases. About half of the cases are idiopathic, with the other half attributable to a predisposing condition or medications being taken.

Pathophysiology

The most common antibody involved in warm antibody AIHA is IgG, though sometimes IgA is found. The IgG antibodies attach to a red blood cell, leaving their FC portion sticking out. The FC region is recognized and grabbed onto by FC receptors found on monocytes and macrophages in the spleen. These cells will pick off portions of the red cell membrane, almost like they are taking a bite. The loss of membrane causes the red blood cells to become spherocytes. Spherocytes are not as flexible as normal RBCs, and will be singled-out for destruction in the red pulp of the spleen as well as other portions of the reticuloendothelial system. The red blood cells trapped in the spleen cause the spleen to enlarge, leading to the splenomegaly often seen in these patients.

The cause of the autoantibody formation is unknown, but the mechanism for drug-induced destruction is better understood. There are two models for this: the hapten model and the autoantibody model. The hapten model proposes that certain drugs, especially penicillin and cephalosporins, will bind to the red cell membrane and act as haptens. Antibodies are created against the cell-drug complex, leading to the destructive sequence described above. The autoantibody model proposes that, through a mechanism not yet understood, certain drugs will cause antibodies to be made against red blood cells which again leads to the same destructive sequence.

Clinical Findings

Laboratory findings include severe anemia, increased mean corpuscular volume (MCV, due to the presence of a large number of young erythrocytes), and hyperbilirubinemia (from increased red cell destruction) that can be of the conjugated or unconjugated type.

Diagnosis

Diagnosis is made by a positive direct Coombs test, other lab tests, and clinical examination and history. The direct Coombs test looks for antibodies attached to the surface of red blood cells.

Treatment

Corticosteroids and immunoglobulins are two commonly used treatments for warm antibody AIHA. Initial Tx consists of prednisone. If ineffective, splenectomy should be considered. If refractory to both these therapies, consider rituximab, danazol, cyclosphosphamide, azathioprine, or cyclosporine, High dose intravenous immune globulin may be effective in controlling hemolysis, but the benefit is short lived (1-4 weeks), and the therapy is very expensive.

References

  • Sacher, Ronald A. and Richard A. McPherson. "Wildman's Clinical Interpretation of Laboratory Tests, 11th edition."
  • Kumar, Vinay, Abul Abbas, and Nelson Fausto. "Robbins and Cotran Pathologic Basis of Disease."

Template:Hematology


Template:WikiDoc Sources